be66e85c-d70d-4073-af6a-bcee51ef3240
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- KRAS_SIGNALING_UP+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- ALLOGRAFT_REJECTION+0.300
- APICAL_SURFACE+0.300
- APOPTOSIS+0.300
- IL2_STAT5_SIGNALING+0.300
Top 10 suppressed
- MYC_TARGETS_V1-0.500
- MYC_TARGETS_V2-0.500
- DNA_REPAIR-0.400
- E2F_TARGETS-0.400
- G2M_CHECKPOINT-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- SPERMATOGENESIS-0.200
- UV_RESPONSE_UP-0.200
- ADIPOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 94f6e4f5-2447-4f1f-9f36-411f1c25a172 | — | — | 0.918 |
| 2 | TCGA-CX-7085-01A-21R-2016-07 | — | — | 0.916 |
| 3 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.914 |
| 4 | fd618c1b-e230-408d-aed8-4ad6df3fc4e6 | — | — | 0.910 |
| 5 | MDT-AP-3277 | Med | Medulloblastoma | 0.908 |
| 6 | TCGA-J2-8192-01A-11R-2241-07 | — | cohortA1 | 0.907 |
| 7 | 67ed15bc-bbe5-4da7-81f9-002c54483f67 | — | — | 0.906 |
| 8 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.906 |
| 9 | TCGA-A2-A0YD-01A-11R-A109-07 | — | A | 0.904 |
| 10 | TCGA-EW-A1J2-01A-21R-A13Q-07 | — | A | 0.901 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |